Some patients with the most common subtype of breast cancer will be able to avoid chemotherapy
–
January 19, 2021
Specifically, these are postmenopausal patients with these markers: positive hormone receptors (RH +), negative epidermal growth factor receptor 2 (HER2), having between 1 and 3 affected axillary nodes and with a result of the so-called recurrence score. which estimates the risk of recurrence and the probability of benefiting from chemotherapy) equal to or less than 25.
Patients with the most frequent subtype of cancer called luminal, who meet these requirements (around 5,300 new cases per year in Spain) and who are currently being treated with chemotherapy plus hormonal therapy, will be able to do without the first and be treated with equal efficacy and forecast only with the second. That is, receive only hormonal therapy and avoid “chemo” and its adverse effects. This is what the RxPONDER study concludes.
This is the first evidence in a randomized phase III clinical trial that postmenopausal women with HR positive and HER2 negative breast cancer that has spread to between one and three lymph nodes can safely forgo chemotherapy if their score of recurrence in the genomic test of tumor tissue is 25 or less.
Source: JANO.
—––
